Oncolytics Biotech (TSE:ONC) PT Raised to C$3.50 at Raymond James

Oncolytics Biotech (TSE:ONC) had its price target hoisted by Raymond James from C$3.00 to C$3.50 in a research report sent to investors on Friday, BayStreet.CA reports.

Oncolytics Biotech Trading Down 2.4 %

Shares of ONC opened at C$1.23 on Friday. The company has a debt-to-equity ratio of 6.09, a current ratio of 4.99 and a quick ratio of 8.86. Oncolytics Biotech has a 1 year low of C$1.20 and a 1 year high of C$3.10. The company has a 50 day simple moving average of C$1.34 and a two-hundred day simple moving average of C$1.42. The firm has a market cap of C$94.54 million, a P/E ratio of -3.24 and a beta of 1.38.

Oncolytics Biotech (TSE:ONC) last posted its earnings results on Thursday, August 1st. The company reported C($0.10) earnings per share for the quarter, hitting analysts’ consensus estimates of C($0.10). On average, equities analysts expect that Oncolytics Biotech will post -0.41 earnings per share for the current fiscal year.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.